Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia ...

Immunovant's (NASDAQ:IMVT) stock and Roivant Sciences (ROIV) stock fall after trial data for the former's autoimmune disease ...

Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus ...

Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in ...

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following ...

The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

The company continues to focus on a next-generation drug while batoclimab’s testing in thyroid eye disease wraps up.

Immunovant (IMVT) reported best absolute improvements with IMVT-1402 in myasthenia gravis and chronic inflammatory demyelinating ...

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...

The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over the trial’s batoclimab. Wednesday, Immunovant, Inc. (NASDAQ ...